Overall Response Rate

Update on checkpoint blockade therapy for lymphoma
Justin Kline, Michael R. Bishop

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (1) 33; DOI: 10.1186/s40425-015-0079-8
High-dose interleukin-2 (hd-IL2) in treatment-naïve metastatic renal cell carcinoma (mrcc) - a 10 year single-site experience and outcome of prospective pathology-based patient selection
Shien Chow, Manon Evans, Victoria Galvis, Rebecca Leach, Elizabeth Keene, Kevin Chan, Andrea Spencer-Shaw, Shanks Jonathan, Alaaeldin Shabalak, Fiona Thistlethwaite, Robert Hawkins

Journal for ImmunoTherapy of Cancer Dec 2014, 2 (Suppl 3) P89; DOI: 10.1186/2051-1426-2-S3-P89
A phase 2 randomized, double-blind, placebo-controlled study of tremelimumab for second and third line treatment in patients with unresectable pleural or peritoneal mesothelioma
Lee Krug, Alessandra di Pietro, Rajesh Narwal, Paul Robbins, Dongyue Fu, Aiman Shalabi, Ramy Ibrahim, Luana Calabro, Hedy Kindler

Journal for ImmunoTherapy of Cancer Nov 2013, 1 (Suppl 1) P132; DOI: 10.1186/2051-1426-1-S1-P132
P27. Alemtuzumab (anti-CD52 monoclonal antibody) as single-agent therapy in patients with relapsed/refractory chronic lymphocytic leukaemia (CLL) – a single region experience on consecutive patients
S Eketorp Sylvan, J Lundin, M Ipek, M Palma, C Karlsson, L Hansson

Journal for ImmunoTherapy of Cancer Mar 2014, 2 (Suppl 2) P18; DOI: 10.1186/2051-1426-2-S2-P18

Main menu